Novo Nordisk to Pay Omeros Up to $2.1 Billion for Blood Disease Drug
By Dominic Chopping
Novo Nordisk will take over a drug being developed to treat rare blood and kidney disorders from Omeros, in a deal that could see the Nasdaq-listed biopharmaceutical company receive up to $2.1 billion.
Under the asset purchase and license agreement, Novo Nordisk will be granted exclusive global rights to develop and commercialize zaltenibart, which has shown positive trial results in treating an autoimmune blood disorder and offers potential to treat some rare renal diseases.
Omeros is eligible to receive $340 million in upfront and near-term milestone payments, and up to a total of $2.1 billion including potential development and commercial milestones on top of tiered royalties on net sales.
"Novo Nordisk is in a strong position to build on the work done by Omeros to maximize the value of this asset and develop zaltenibart into a differentiated and potentially best-in-class treatment approach for a number of rare blood and kidney disorders," said Martin Holst Lange, chief scientific officer and executive vice president of research and development at Novo Nordisk.
Novo Nordisk has previously pledged to broaden its pipeline of rare-disease drugs and late last year announced plans to invest $1.2 billion in new production facilities in Denmark.
Write to Dominic Chopping at dominic.chopping@wsj.com
(END) Dow Jones Newswires
October 15, 2025 09:27 ET (13:27 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy Before They Rise Further
2 Undervalued Stocks to Buy Before They Rebound
The 10 Best Companies to Invest in Now
The 10 Best Dividend Stocks
United States